Cipla takes deal route with Alvotech to enter Australian autoimmune biosimilars market: GlobalData Read more
Mylan-UpJohn merger as Viatris provides opportunity to focus on biosimilar launch and uptake Read more
CRISPR-based cancer therapies likely to be a disruptive technology in healthcare: GlobalData Read more
Low patient accrual rates cause termination of over 25 per cent rare disease trials: GlobalData Read more